Health TrialsbyHealthPanel

Impact of Capillary Leak and Hypoalbuminemia on PK/PD of Anidulafungin and Caspofungin in Critically Ill Patients

ConditionCritically Ill Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversitaire Ziekenhuizen KU Leuven

About this trial

This prospective study will explore the pharmacokinetic exposure and pharmacodynamics of the echinocandins (caspofungin or anidulafungin) in critically ill patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Treatment with anidulafungin or caspofungin

Admitted to an ICU ward

Disqualifiers

< 18 years

DNR 2 or 3

Trial population

Critically ill patients.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • Sample collection

    Other intervention

    Plasma and BAL sample collection

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Area under the curve (AUC)

The area under the concentration-time curve will be calculated

Time frame
July 2020
2

Half-life (T1/2)

The half-life will be calculated

Time frame
July 2020
3

Volume of distribution (Vd)

The volume of distribution will be calculated

Time frame
July 2020
4

Clearance (CL)

The clearance will be calculated

Time frame
July 2020

Secondary outcomes

1

Influence of serum creatinin (mg/dL) on echinocandin-exposure

Time frame
July 2020
2

Influence of glomerular filtration rate (ml/min) on echinocandin-exposure

Time frame
July 2020
3

Influence of on bilirubin on echinocandin-exposure

Time frame
July 2020
4

Influence of gamma-GT on echinocandin-exposure

Time frame
July 2020

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Universitaire Ziekenhuizen KU Leuven

Lead sponsor

KU Leuven

Collaborator

Source ClinicalTrials.gov
Apply now